EU-FDA MRA to be expanded
Recommendation
11/12 February 2025
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
It has not yet been fully implemented - and we are already talking about an enlargement. The Mutual Recognition Agreement (MRA) with the USA was extended in 2018 to include further countries: Czech Republic, Greece, Hungary, Romania, Ireland, Lithuania, Portugal, Belgium, Denmark, Estonia, Finland, Latvia. Some countries, including Germany, are still not part of the agreement. (Here you will find an overview of the current status). By 15 July 2019, however, all authorities and countries should have been approved and included.
Now, there are already discussions about extending the scope of the MRA. It is to be extended to veterinary medicinal products in the medium term. Later, until 2022, the MRA is to be extended to include joint inspections of production facilities for human vaccines and plasma derivatives. An action plan will be drawn up for this purpose in 2019. This is stated in an interim report of the Executive Working Group EWG.
Related GMP News
05.02.2025European Shortages Monitoring Platform (ESMP) goes live
05.02.2025The ICH Q9 Briefing Package - a Forgotten Document?
23.01.2025FDA proposes Standardized Testing for Asbestos in Talc-Containing Cosmetic Products
16.01.20252nd Version of the Union list of Critical Medicines published
16.01.2025Securing Europe's Drug Supply: How EDSForm is Addressing Medicine Shortages